Featured Stories

Indiana Woman Alleges Serious Injuries From Transvaginal Mesh Products

Parker Waichman LLP, a national law firm, just filed a lawsuit on behalf of a woman who suffered injuries after receiving transvaginal mesh implants. The lawsuit suit alleges that the transvaginal mesh created an unreasonable risk and directly caused her injuries.

Read More

Post -Tonsillectomy Morphine Life-Threatening in Children

Post -Tonsillectomy Morphine can be Life-Threatening in Children, Study Finds

A new study published in Pediatrics suggests that morphine can result in life-threatening respiratory problems when given to children after a tonsillectomy.

Read More

Canadian Warning Issued for Actos Bladder Cancer Side Effect Risk

Health Canada has become the most recent national drug regulator to issue a warning about Actos and bladder cancer. Last month, the agency warned that interim results from a 10-year-study indicated that patients taking Actos for more than a year faced an increased risk of bladder cancer. Health Canada also ...

Read More

Estate of Kentucky Man Alleges Wrongful Death Due to Actos Bladder Cancer

National law firm, Parker Waichman LLP, just filed a lawsuit on behalf of the estate of a Kentucky man who developed bladder cancer and subsequently died, allegedly due to the use of diabetes drug, Actos. The lawsuit names Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals USA, Inc., Takeda Pharmaceuticals North America, ...

Read More

Hip Replacement, Knee Implant Patients with Diabetes, Other Health Problems May Face Difficult Recoveries

Patients receiving hip replacement devices or knee implants may face a more complicated recovery if they are obese, or suffer from diabetes or other health woes. According to a new study published online in the journal Anesthesiology, at least 3% of all total hip or knee replacement patients will ...

Read More

Study Finds SSRI Antidepressant Side Effects Outweigh Their Benefits

A new study is raising more concerns about the safety of commonly used antidepressants, including selective serotonin reuptake (SSRI) inhibitor antidepressants. Investigators who conducted the study, which is published in the journal Frontiers in Psychology, posit that increased knowledge of the negative effects of SSRIs and other antidepressants could reduce ...

Read More

DePuy ASR Hip Implants, Other Faulty Medical Devices Subject to Little FDA Oversight, Investigation Finds

A newly-published investigation from ProPublica has revealed that several questionable types of medical devices, including DePuy Orthopaedic’s recalled ASR hip implant, managed to make it to market without much scrutiny on the part of the U.S. Food & Drug Administration (FDA).

Read More

Knee Replacement Patients Should Consider Nickel Allergies before Surgery

Individuals considering undergoing knee replacement surgery should ask their doctors to run a test to determine if they have a nickel allergy. Determining if a patient suffers from a nickel allergy will ensure the right knee implant is chosen for their surgery, and possibly save them from considerable pain and ...

Read More

Actos Bladder Cancer Lawsuits Continue, New Complaint Filed by Tennessee Resident

Actos bladder cancer lawsuits continue, with a new complaint filed by a resident of Tennessee. The national law firm, Parker Waichman LLP, represents the Tennessee man who alleges that Actos caused his bladder cancer.

Read More

System for Tracking Prescription Drug Side Effects Flawed

Study Finds System for Tracking Prescription Drug Side Effects Flawed

System for keeping track of dangerous side effects of prescription drugs is flawed because drug makers are submitting incomplete information about problems to the FDA.

Read More

Jury in Washington State Awards $1 Million to Plaintiff “Perceived” as Whistleblower

Continue reading

Posted in Legal News, Whistleblower |

OriGen VV13F Reinforced Dual Lumen ECMO Catheters Recalled Due to Risk of Tube Separation

OriGen Biomedical recalled one lot of 51 VV13F Reinforced Dual Lumen ECMO Catheters, according to a recall alert posted on the U.S. Food and Drug Administration’s (FDA’s) website. The devices were recalled due to the risk of the clear extension tube separating from the hub in which it is inserted. Intervention may be needed to prevent permanent impairment or damage if this occurs. The recall affects lot N18549, which expires 09/2018. OriGen knows of at least one product failure, which is associated with a serious adverse event that led to a serious patient injury, the recall indicated. Continue reading

Posted in Legal News |

Beech-Nut Recalls Baby Food Over Possible Glass Contamination

On Tuesday, the U.S. Department of Agriculture’s Food Safety and Inspection Service (FSIS) announced that Beech-Nut Nutrition is recalling approximately 1,920 pounds of baby food products that may be contaminated with small pieces of glass.

The recalled baby food was produced on December 12, 2014. The following product is subject to recall:

  • 4-oz. glass jars containing “Stage 2 Beech-Nut CLASSICS sweet potato & chicken”

Continue reading

Posted in Defective Products, Food Products |

9/11 Responders and Workers Release Video Urging Extension of Zadroga Act

An advocacy group for 9/11 responders and clean-up workers, Citizens for the Extension of the James Zadroga Act, has released a video, urging Congress to renew the James Zadroga 9/11 Health and Compensation Act. The Zadroga Act provides treatment and compensation for those who were injured or became ill after exposure to toxins in the aftermath of the 9/11 World Trade Center terrorist attacks.

The World Trade Center Health Program and the September 11th Victim Compensation Fund— key provisions of the act—will expire in October 2015 and October 2016, respectively, unless the Zadroga Act is renewed. U.S. Senator Kirsten Gillibrand is leading the effort for the Zadroga Act renewal. Gillibrand was a sponsor of the original legislation in 2010. Continue reading

Posted in Health Concerns, Toxic Substances, Zadroga Act Claims |

Concern About Conflicts of Interest in FDA Dietary Supplement Regulators

Concern About Conflicts of Interest in FDA Regulators

Concern About Conflicts of Interest in FDA Regulators

The Food and Drug Administration (FDA) is facing criticism of its regulation of dietary supplements containing a dangerous stimulant. The stimulant is BMPEA, a chemical nearly identical to amphetamine. BPMEA is added to weight-loss and workout products to enhance their effect.

BPMEA has never been tested for safety and effectiveness in humans and is not a permissible ingredient in dietary supplements. The FDA was the first agency to suspect that BMPEA had been added to supplements that listed the little-known plant acacia rigidula among the ingredients. Experts say that plant listings like this are often an indication that the manufacturer is trying to disguise a chemical additive as a natural botanical extract, the New York Times reports. Continue reading

Posted in Defective Products, Health Concerns | Tagged , , , |

Tri-Methyl Xtreme Supplements May Lead to Liver Damage, FDA Says

Tri-Methyl Xtreme Supplements May Lead to Liver Damage

Tri-Methyl Xtreme Supplements May Lead to Liver Damage

The U.S. Food and Drug Administration (FDA) is warning that Tri-Methyl Xtreme, a muscle-building supplement sold by Las Vegas company Extreme Products Group, has been linked to liver damage. According to Associated Press, the supplement was linked to three reported injuries in California, New Jersey and Utah. The FDA began investigating the product following these reports.

Tri-Methyl Xtreme claims to contain anabolic steroids, although it is sold as a dietary supplement. Dr. Charles Lee of the FDA drug center’s office of compliance said that anabolic steroids “may have a range of serious adverse effects on many organ systems, and the damage may be irreversible,” according to Wall Street Journal. The FDA warned that these chemicals can also negatively impact cholesterol levels, increase the risk of heart attack and stroke, cause masculinity in women and lead to testicle shrinkage. Continue reading

Posted in Legal News | Tagged , , , , |

FDA Warns Wrinkle Cream Maker About Overstated Claims

FDA Warns Wrinkle Cream Maker About Overstated Claims

FDA Warns Wrinkle Cream Maker About Claims

The Food and Drug Administration (FDA) is warning the beauty industry about some of the claims being made for some of its products. Five warnings letters have gone out to companies since November.

The most recent warning letter went out to StriVectin, whose wrinkle creams are sold by a wide range retailers, including Costco and Nordstrom, the Today show reports. The FDA objects to language in the ads that makes the products seem like drugs, not cosmetics. The language includes Continue reading

Posted in Defective Products | Tagged , , , , |

FDA Should Ban Dietary Supplements, Senator Schumer Says

FDA Should Ban Dietary Supplements, Senator Schumer Says

FDA Should Ban Dietary Supplements, Senator Schumer Says

On Sunday, United States Senator Chuck Schumer called on the U.S. Food and Drug Administration (FDA) to ban dietary supplements, WHEC Rochester reports. Schumer says the ban should be implemented due to evidence showing that popular supplement products contain hidden stimulants. Many products contain an addictive, amphetamine-like chemical that is not listed on the label, Schumer said. The senator emphasized that the unknown ingredient can be dangerous for users, and that the FDA should issue a recall.

A recent study published in the journal Drug Testing and Analysis identified a number of supplements containing BMPEA, a substance similar to amphetamine. Supplements found to contain the substance include Aro Black Series Burn, Black Widow, Dexaprine XR, Fastin-XR, Lipodrene Hardcore, Lipodrene Xtreme, Stimerex-ES and Yellow Scorpion. Researchers conducted the analysis after being unable to get answers from the FDA, who found BMPEA in nine out of 21 samples in a 2013 study but would not name the products. Continue reading

Posted in Defective Products, Health Concerns, Legal News, Pharmaceuticals | Tagged , , , , |

FDA Says Diabetes Drug Onglyza May be Linked to Higher Death Rate

FDA Says Diabetes Drug Onglyza Linked to Higher Death Rate

FDA Says Diabetes Drug Onglyza Linked to Death Rate

After conducting a preliminary review of data, the U.S. Food and Drug Administration (FDA) has issued a report indicating that AstraZeneca’s diabetes drug Onglyza may be linked with an increased rate of death. According to Reuters, an FDA advisory panel will meet on April 14 to discuss he risks of Onglyza and another similar drug.

Previous findings from the SAVOR trial, which was comprised of 16,000 patients taking Onglyza, showed that the drug was associated with an increased risk of hospitalization due to heart failure. The FDA reviewed the data and determined that the risk of heart failure is legitimate. Additionally, the FDA found that Onglyza may be linked to an increased risk of death from all causes. Even though the overall trial results did not point to an increased death risk, the agency’s review found that the drug may pose “a significantly increased risk of all-cause mortality,” upon further analysis. Continue reading

Posted in Legal News | Tagged , , , , |

FDA Says Some Generic ADHD Medications May Not be as Effective

FDA Says Some Generic ADHD Medications Not as Effective

FDA Says Some Generic ADHD Medications Not as Effective

The U,S, Food and Drug Administration (FDA) has raised questions about the effectiveness of two generic medications used to treat attention deficit hyperactivity disorder (ADHD). The agency said in November that generic versions of Concerta, the long-acting version of Ritalin, may not be “therapeutically equivalent” to the brand name and may not have the same benefits,

“Two of these generics, so to speak, were not exactly providing the same rate and extent of absorption of medicine that Concerta had,” said Dr. Andrew Adesman of Steven and Alexandra Cohen Children’s Medical, according to CBS. Continue reading

Posted in Legal News | Tagged , , , , |

© 2005-2014 Parker Waichman LLP ®. All Rights Reserved.